DISC MEDICINE INC.

NASDAQ: IRON (Disc Medicine, Inc.)

Last update: 08 Jun, 3:04PM

50.02

2.01 (4.19%)

Previous Close 48.01
Open 48.96
Volume 216,637
Avg. Volume (3M) 438,615
Market Cap 1,732,407,680
Price / Book 2.63
52 Weeks Range
30.82 (-38%) — 68.73 (37%)
Earnings Date 6 Aug 2025 - 11 Aug 2025
Diluted EPS (TTM) -3.89
Total Debt/Equity (MRQ) 4.64%
Current Ratio (MRQ) 37.65
Operating Cash Flow (TTM) -101.70 M
Levered Free Cash Flow (TTM) -66.74 M
Return on Assets (TTM) -16.25%
Return on Equity (TTM) -23.33%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Bearish Bearish
Biotechnology (Global) Bearish Bearish
Stock Disc Medicine, Inc. Bullish Bullish

AIStockmoo Score

0.5
Analyst Consensus 5.0
Insider Activity -2.5
Price Volatility -2.0
Technical Moving Averages 0.0
Technical Oscillators 2.0
Average 0.50

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
IRON 2 B - - 2.63
PTCT 4 B - 7.87 -
CRNX 3 B - - 2.28
VRDN 1 B - - 3.12
KALV 648 M - - 4.61
ARVN 543 M - - 0.820

Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company’s preclinical programs include DISC-0998.

Sector Healthcare
Industry Biotechnology
Investment Style Small Core
% Held by Insiders 10.57%
% Held by Institutions 98.94%
52 Weeks Range
30.82 (-38%) — 68.73 (37%)
Price Target Range
89.00 (77%) — 120.00 (139%)
High 120.00 (BMO Capital, 139.90%) Buy
Median 118.00 (135.91%)
Low 89.00 (Raymond James, 77.93%) Buy
Average 109.00 (117.91%)
Total 3 Buy
Avg. Price @ Call 49.17
Firm Date Target Price Call Price @ Call
HC Wainwright & Co. 17 Jun 2025 118.00 (135.91%) Buy 50.05
Raymond James 11 Jun 2025 89.00 (77.93%) Buy 50.86
BMO Capital 12 May 2025 120.00 (139.90%) Buy 46.61
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
FRANCHI JEAN M. - 52.02 -2,000 -104,040
Aggregate Net Quantity -2,000
Aggregate Net Value ($) -104,040
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 52.02
Name Holder Date Type Quantity Price Value ($)
FRANCHI JEAN M. Officer 16 Jun 2025 Automatic sell (-) 2,000 52.02 104,040

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria